Advertisement


Olivier Tredan, MD, PhD, on Advanced Refractory Cancer and Molecular Screening

2017 ASCO Annual Meeting

Advertisement

Olivier Tredan, MD, PhD, of the Centre Léon Bérard, discusses results from ProfilER, a study that explored the use of cancer cell genomic alterations to guide treatment in patients with advanced refractory cancer. (Abstract LBA100)



Related Videos

Neuroendocrine Tumors

Greta Stifel on Neuroendocrine Tumors: A Patient's Message to Physicians 

Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.

Kidney Cancer

Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers

Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)

Lung Cancer

Solange Peters, MD, PhD, on SCLC: Expert Perspective on CheckMate 032

Solange Peters, MD, PhD, of the University of Lausanne, examines the study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)

Supportive Care
Issues in Oncology

Gary Rodin, MD, on Advanced Cancer: The CALM Psychological Intervention

Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Advertisement

Advertisement




Advertisement